secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sorrento Therapeutics, Inc. (—)
CIK:        0000850261
Form:       8-K
Filed at:   2023-09-26T23:59:59+00:00
Accession:  0001104659-23-103911
Event type: m_and_a
Sentiment:  negative
Materiality: 0.85
Item codes: 1.01, 1.02, 2.01, 9.01, 7.01, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Sorrento completes sale of Scilex stake for $110M; deconsolidates Scilex, cuts headcount
--------------------------------------------------------------------------------

- Scilex acquired all Sorrento's Scilex shares for $110M (incl. $100M DIP assumption), plus $12.25M legal fees and $23M credit bid.
- Sorrento no longer holds controlling interest; Scilex to be deconsolidated and presented as discontinued operations.
- Terminated Oramed SPA (previous $105M stalking-horse bid) via mutual termination agreement on Sept 21, 2023.
- Reduced workforce from 215 to 128 employees on Sept 20, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/850261/000110465923103911/0001104659-23-103911-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/850261/000110465923103911/tm2326887d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-103911

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer